The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas

BACKGROUND: Spinal neurofibromas (SNFs) in neurofibromatosis type 1 (NF1) can cause progressive spinal cord compression and neurological dysfunction. The MEK inhibitor selumetinib shrinks the majority of plexiform neurofibromas (PNs) in patients with NF1. We assessed the effect of selumetinib on SNF...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neurooncol Adv
Hlavní autoři: Jackson, Sadhana, Baker, Eva H, Gross, Andrea M, Whitcomb, Patricia, Baldwin, Andrea, Derdak, Joanne, Tibery, Cecilia, Desanto, Jennifer, Carbonell, Amanda, Yohay, Kaleb, O’Sullivan, Geraldine, Chen, Alice P, Widemann, Brigitte C, Dombi, Eva
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2020
Témata:
Clinical Investigations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7486535/
https://ncbi.nlm.nih.gov/pubmed/32939452
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa095
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky